Titan Pharmaceuticals
TTNP
3,48 €
Share price
-8.22%
Change (1 day)
-33.97%
Change (1 year)
Categories
Operating Margin for Titan Pharmaceuticals (TTNP)
Operating Margin as of July 2025 (TTM): -556,900.00%
According to Titan Pharmaceuticals 's latest financial reports and stock price the company's current Operating Margin is -556,900.00%. At the end of 2023 the company had an Operating Margin of -556,900.00%.
Operating Margin history for Titan Pharmaceuticals from 2001 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2023 | -556,900.00% | 3173.96% |
| 2022 | -17,010.00% | 382.62% |
| 2021 | -3,524.50% | 156.47% |
| 2020 | -1,374.21% | -42.21% |
| 2019 | -2,377.78% | 1457.69% |
| 2018 | -152.65% | -97.71% |
| 2017 | -6,654.42% | -19622.65% |
| 2016 | 34.09% | -105.05% |
| 2015 | -674.99% | 924.13% |
| 2014 | -65.91% | -171.13% |
| 2013 | 92.65% | -143.44% |
| 2012 | -213.29% | -42.93% |
| 2011 | -373.72% | 451.94% |
| 2010 | -67.71% | -99.08% |
| 2009 | -7,360.76% | |
| 2007 | -76,804.17% | 49.43% |
| 2006 | -51,396.88% | 98.44% |
| 2005 | -25,900.00% | -68.66% |
| 2004 | -82,648.39% | 169.66% |
| 2003 | -30,649.44% | 2669.68% |
| 2002 | -1,106.60% | 109.5% |
| 2001 | -528.22% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Vanda Pharmaceuticals VNDA | -35.98% | -99.99% | 🇺🇸 USA |
 MediciNova MNOV | -856.84% | -99.85% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -2,248.76% | -99.60% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 18.78% | -100.00% | 🇺🇸 USA |
 Novartis NVS | 28.02% | -100.01% | 🇨🇭 Switzerland |
 Repligen
RGEN | -4.26% | -100.00% | 🇺🇸 USA |
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.